Proscia's software platform is used by 14 of the top 20 pharmaceutical companies to leverage pathology image data for drug discovery and development. With the FDA clearance, Proscia can now bring its digital pathology solutions to diagnostic labs, addressing the global pathologist shortage and rising cancer rates. The company's AI applications automate tasks such as quality control and tumor identification, enabling pathologists to work more efficiently.
Key takeaways:
- Proscia, a digital pathology software provider, has raised $9 million in an extension of its Series C funding round, bringing the total round to $46 million.
- The funding will be used to accelerate Proscia’s commercial growth and further develop its AI-powered applications for life sciences and diagnostic laboratories.
- Proscia's software platform is already used by 14 of the top 20 pharmaceutical companies, and with recent FDA clearance, it can now bring its digital pathology solutions to diagnostic labs.
- As digital pathology adoption accelerates, Proscia is well-positioned to lead the transformation with its AI applications that automate tasks such as quality control and tumor identification.